BioVex Ltd.
This article was originally published in Start Up
Executive Summary
London-based BioVex Ltd. believes it has found a way to harness the herpes-simplex virus I as a delivery vehicle for genes. The firm expects its vectors to be especially well-suited for neurological diseases, but adaptable to others including cancer and immunological conditions. BioVex also hopes to interest Big Pharma partners in its vectors as research tools.